Lunaphore continues U.S. expansion with completion of U.S. C corporation registration to support growing base of customers
LAUSANNE, Switzerland – June 9, 2022 – 4:00 pm (CEST) – Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced it has successfully completed registration as a C corporation in the United States as part of its continuing global expansion to serve customers and partners in the translational and clinical research markets.
Lunaphore has recruited industry veterans to bring its spatial biology technology and expertise to support a growing base of U.S. customers. Registration in the U.S. will enable Lunaphore to continue expanding its team. Currently, Lunaphore has over 100 employees globally.
“Lunaphore is growing exponentially, and our U.S. presence will help address the increasing demand for our spatial biology technology across translational and clinical research,” said Ata Tuna Ciftlik, Chief Executive Officer at Lunaphore. “We are excited to have already deployed our products at several leading medical institutions in the U.S. and we look forward to scaling our operations in the coming years to service our U.S. partners.”
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies.
For further information contact:
Lunaphore Corporate Communications
Email: [email protected]